Results 151 to 160 of about 662,616 (328)
Extended range proteomic analysis of blood plasma from schizophrenia patients
Frontiers in Molecular BiosciencesIntroductionThe high prevalence of schizophrenia worldwide makes it necessary to proceed from subjective assessment of patient’s clinical symptoms in diagnosis making to searching for circulating blood biomarkers. On the one hand, searching for molecular
Denis V. Petrovskiy +10 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis [PDF]
, 2022 Haijie Liu +7 more
openalex +1 more source
Discovery and Targeted Proteomic Studies Reveal Striatal Markers Validated for Huntington's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Clinical trials for Huntington's disease (HD) enrolling persons before clinical motor diagnosis (CMD) lack validated biomarkers. This study aimed to conduct an unbiased discovery analysis and a targeted examination of proteomic biomarkers scrutinized by clinical validation. Methods Cerebrospinal fluid was obtained from PREDICT‐HD and
Daniel Chelsky +8 more
wiley +1 more source
Metaproteomics for analysis of microbial function in the environment [PDF]
, 2007 This report briefly describes the approach of using proteomic analyses to examine protein expression directly from environmental samples (termed metaproteomics).
Bond, PL, Wexler, M
core
Arthritis Care &Research, Accepted Article.Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla +13 more
wiley +1 more source
Alterations of Spermatozoa Proteomic Profile in Men with Hodgkin's Disease Prior to Cancer Therapy
, 2019 Ana D. Martins +5 more
openalex +1 more source
P2‐119: PROTEOMICS‐BASED CSF BIOMARKERS IN FAMILIAL FRONTOTEMPORAL DEMENTIA [PDF]
, 2014 Nina Rostgaard +4 more
openalex +1 more source